Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru

There are approximately 72,000 people living with HIV/AIDS (PLHIV) in Peru. Non-adherence to antiretroviral therapy (ART) is the most important factor for therapeutic failure and the development of resistance. Peru has achieved moderate progress in meeting the 90-90-90 targets, but only 60% of PLHIV...

Descripción completa

Detalles Bibliográficos
Autores: Leyva Moral, Juan M.|||0000-0003-4241-4992, Loayza-Enriquez, Blanca K., Palmieri, Patrick A.|||0000-0002-0765-0239, Guevara Vásquez, Génesis Masiel|||0000-0003-0329-3825, Elias-Bravo, Ursula E., Edwards, Joan E.|||0000-0001-5415-1064, Feijoo Cid, Maria|||0000-0002-7010-373X, Davila-Olano, Lucy Y., Rodriguez-Llanos, Juan R., Leon-Jimenez, Franco E.
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:226599
Acceso en línea:https://ddd.uab.cat/record/226599
https://dx.doi.org/urn:doi:10.1186/s12981-019-0238-y
Access Level:acceso abierto
Palabra clave:HIV: Human Immunodeficiency Virus
AIDS: Acquired Immune Deficiency Syndrome
ART: Antiretroviral therapy
Adherence
SMAQ: Simplified Medication Adherence Questionnaire
Peru
PLHIV: People living with HIV
Compliance
Descripción
Sumario:There are approximately 72,000 people living with HIV/AIDS (PLHIV) in Peru. Non-adherence to antiretroviral therapy (ART) is the most important factor for therapeutic failure and the development of resistance. Peru has achieved moderate progress in meeting the 90-90-90 targets, but only 60% of PLHIV receiving ART are virally suppressed. The purpose of this study was to understand ART adherence in the Peruvian context, including developing sociodemographic and clinical profiles, evaluating the clinical management strategies, and analyzing the relationships between the variables and adherence of PLHIV managed at a regional HIV clinic in Lambayeque Province (Northern Peru). This was a cross-sectional study with 180 PLHIV adults, non-randomly but consecutively selected with self-reported ART compliance (78.2% of the eligible population). The PLHIV profile (PLHIV-Pro) and the Simplified Medication Adherence Questionnaire (SMAQ) were used to collect sociodemographic information, clinical variables, and data specific to ART adherence. Descriptive analysis of sociodemographic and clinical characteristics was performed. Bivariate analysis was performed with the Mann-Whitney test, Chi square test, and Yates correction. The 180 PLHIV sample included 78.9% men, 49.4% heterosexual, 45% with a detectable HIV-1 viral load less than 40 copies/ml, 58.3% not consistently adherent, and only 26.1% receiving Tenofovir + Lamivudine + Efavirenz. Risk factors significant for non-adherence included concurrent tuberculosis, discomfort with the ART regime, and previous pauses in ART. Multivariate analysis of nested models indicated having children is a protector factor for adherence. Self-reported adherence appeared to be low and the use of first-line therapy is not being prescribed homogeneously. Factors associated with nonadherence are both medical and behavioral, such as having tuberculosis, pausing ART, or experiencing discomfort with ART. The Peruvian government needs to update national technical standards, monitor medication availability, and provide education to health care professionals in alignment with evidence-based guidelines and international recommendations. Instruments to measure adherence need to be developed and evaluated for use in Latin America.